Want to see IN:BAFNAPH full AI Analyst Report?
Top Page
Bafna Pharmaceuticals Limited
(BAFNAPH)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹406.00
▲(162.53% Upside)
Action:Reiterated
Date:09/08/26
The score is driven most by uneven fundamentals—especially persistently negative free cash flow and margin volatility—partly offset by a strong technical uptrend (price above key moving averages with positive MACD). Valuation is a clear headwind due to the very high P/E and no stated dividend support.
Positive Factors
Multi-year Revenue Expansion
Strong multi-year revenue expansion indicates the company has increased its business scale and maintained demand across the period. Although growth has not been consistent every year, a larger revenue base can support operating leverage, broader market reach, and continued investment in pharmaceutical formulations.
Negative Factors
Persistently Negative Free Cash Flow
Recurring negative free cash flow indicates that reinvestment and/or working-capital needs are absorbing cash despite reported profits. If sustained, this reduces the funds available for growth, debt reduction, and shareholder returns, while increasing reliance on financing to maintain business activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year Revenue Expansion
Strong multi-year revenue expansion indicates the company has increased its business scale and maintained demand across the period. Although growth has not been consistent every year, a larger revenue base can support operating leverage, broader market reach, and continued investment in pharmaceutical formulations.
Read all positive factors
Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.11B
Dividend Yield1.93%
Average Volume (3M)4.14K
Price to Earnings (P/E)115.1
Beta (1Y)0.63
Revenue Growth-3.14%
EPS Growth-5.80%
CountryIN
Employees339
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.29
Shares Outstanding23,656,336
10 Day Avg. Volume5,565
30 Day Avg. Volume4,145
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bafna Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countrie...
How the Company Makes Money
Bafna Pharmaceuticals Limited makes money primarily by selling pharmaceutical formulations (finished dosage products) to customers in its served markets. Key revenue streams typically include (i) sales of branded or generic formulations through do...
Bafna Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.51B | 1.46B | 1.52B | 1.15B | 851.40M |
| Gross Profit | 329.05M | 201.42M | 168.77M | 452.15M | 175.56M | 137.18M |
| EBITDA | 163.50M | 207.04M | 117.73M | 146.34M | 189.88M | 112.34M |
| Net Income | 77.86M | 111.00M | 41.52M | 73.48M | 113.38M | 52.16M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.76B | 1.53B | 1.48B | 1.30B | 901.45M |
| Cash, Cash Equivalents and Short-Term Investments | 20.25M | 20.25M | 34.33M | 13.96M | 78.09M | 194.00K |
| Total Debt | 0.00 | 374.33M | 281.99M | 243.89M | 229.24M | 110.59M |
| Total Liabilities | -961.50M | 793.83M | 682.73M | 668.43M | 561.29M | 281.81M |
| Stockholders Equity | 961.50M | 961.50M | 848.07M | 808.39M | 734.55M | 619.64M |
Cash Flow | ||||||
| Free Cash Flow | -71.04M | -130.76M | -23.31M | -60.93M | -32.66M | 21.87M |
| Operating Cash Flow | 93.13M | 118.27M | 195.29M | 94.85M | 49.52M | 97.28M |
| Investing Cash Flow | -149.13M | -224.69M | -213.02M | -150.54M | -74.93M | -65.44M |
| Financing Cash Flow | 24.23M | 92.35M | 38.09M | -8.45M | 101.77M | -48.15M |
Bafna Pharmaceuticals Limited Technical Analysis
Positive
154.65
Price Trends
293.86
Positive
236.11
Positive
182.00
Positive
Market Momentum
25.15
Negative
84.50
Negative
99.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 154.65 is below the 20-day moving average (MA) of 328.90, below the 50-day MA of 293.86, and below the 200-day MA of 182.00, indicating a bullish trend. The MACD of 25.15 indicates Negative momentum. The RSI at 84.50 is Negative, neither overbought nor oversold. The STOCH value of 99.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.
Bafna Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹69.82B | 21.62 | ― | 4.06% | -8.88% | -10.68% | |
71 Outperform | ₹74.91B | 37.53 | ― | 0.11% | 28.14% | 11.38% | |
63 Neutral | ₹7.55B | 24.93 | ― | 0.40% | 14.04% | 2.57% | |
61 Neutral | ₹9.11B | 115.12 | ― | 1.93% | -3.14% | -5.80% | |
58 Neutral | ₹339.03B | 82.56 | ― | 1.27% | 18.37% | ― | |
56 Neutral | ₹26.90B | -79.74 | ― | 0.27% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:BAFNAPH
Bafna Pharmaceuticals Limited
385.00
214.00
125.15%
IN:HIKAL
Hikal Limited
218.15
-34.14
-13.53%
IN:KILITCH
Kilitch Drugs (India) Limited
216.05
30.60
16.50%
IN:SANOFI
Sanofi India Limited
3,031.55
-1,621.01
-34.84%
IN:SUPRIYA
Supriya Lifescience Limited
930.70
204.56
28.17%
IN:WOCKPHARMA
Wockhardt Limited
2,086.50
657.95
46.06%
Bafna Pharmaceuticals Limited Corporate Events
Bafna Pharmaceuticals Shuts Trading Window Ahead of Q2 FY27 Results
Sep 26, 2026
Bafna Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line with the SEBI (Prohibition of Insider Trading) Regulations and its own insider trading code. The window wil...
Bafna Pharmaceuticals Files SEBI Demat Compliance Certificate for June Quarter
Jul 9, 2026
Bafna Pharmaceuticals Limited, a Chennai-based drug maker listed on Indian exchanges, manufactures pharmaceuticals from its facilities in Tamil Nadu and relies on professional registrar and transfer agent services to handle its equity-related comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.